Home › Cancro ai polmoni › Kansas › Overland Park
Studi clinici su Cancro ai polmoni a Overland Park, KS
11 studi su Cancro ai polmoni cercano partecipanti presso sedi a Overland Park e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
In reclutamentoFase 3
- Saint Luke's South Hospital, Overland Park
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
In reclutamentoFase 1/2
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · a 3 mi di distanza
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
In reclutamentoFase 3
- University of Kansas Cancer Center-Overland Park, Overland Park
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
In reclutamentoFase 3
- University of Kansas Cancer Center-Overland Park, Overland Park
Integrated Cancer Repository for Cancer Research
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Saint Luke's Cancer Instititute - South, Overland Park
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
In reclutamentoFase 2
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · a 3 mi di distanza
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
In reclutamentoFase 2/3
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · a 3 mi di distanza
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
In reclutamentoFase 2
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · a 3 mi di distanza
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
In reclutamentoFase 1/2
- The University of Kansas Cancer Center, Fairway · a 3 mi di distanza
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
In reclutamentoStudio osservazionale
- Aton Health, Leawood · a 3 mi di distanza
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
In reclutamentoStudio osservazionale
- The University of Kansas Cancer Center (KUCC), Fairway · a 3 mi di distanza
Studi su Cancro ai polmoni in altre città
- Houston, TX78 studi
- Boston, MA62 studi
- New York City, NY60 studi
- Los Angeles, CA45 studi
- Arlington, VA41 studi
- Washington, DC41 studi
- Chicago, IL41 studi
- Baltimore, MD40 studi
- Nashville, TN40 studi
- St. Louis, MO39 studi
- Columbus, OH37 studi
- Philadelphia, PA36 studi
Altri studi a Overland Park
- Cancro del polmone non a piccole cellule16 studi
- Leucemia mieloide acuta11 studi
- Cancro al seno10 studi
- Fibrillazione atriale8 studi
- Cancro colorettale8 studi
- Obesità7 studi
- Cancro pancreatico7 studi
- Cancro alla prostata7 studi
- Melanoma6 studi
- Sovrappeso6 studi
- Cancro ovarico6 studi
- Cancro (tutti i tipi)5 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.